



# SARS-CoV-2: a potential novel etiology of fulminant myocarditis

## Coronaviruses

Coronaviruses are enveloped nonsegmented positive-sense RNA viruses, which are broadly distributed in humans and other mammals, including camels, bats, masked palm civets, mice, dogs, and cats [1]. Although most human coronavirus infections are mild, coronaviruses have caused two large-scale pandemics in the last two decades: severe acute respiratory syndrome (SARS) with a mortality rate of 10%, and Middle East respiratory syndrome (MERS) with a mortality rate of 37%, together causing more than 10,000 cumulative cases [2, 3].

In December 2019, the Chinese city of Wuhan became the center of an outbreak of pneumonia of unknown cause [4]. Several patients with viral pneumonia were found to be epidemiologically associated with the Huanan seafood market in Wuhan, where a number of non-aquatic animals such as birds and rabbits were also on sale [5]. Bronchoalveolar lavage fluid (BALF), oral swabs, anal swabs, and blood samples from patients with severe pneumonia were investigated for pathogen diagnosis at the early stage of the outbreak. Soon, a novel coronavirus was isolated from patients, and the SARS-CoV-2, previously named “2019 novel coronavirus” (2019-nCoV), was identified using next-generation sequencing [6].

Usually, RNA viruses have a high mutation rate, but a notable common characteristic of both SARS-CoV and MERS-CoV is that they have a low potential for sustained community transmission

[7]. Thus, the mutation rate of coronaviruses might also be lower because of their genome-encoded exonuclease [4].

## SARS-CoV-2 infection

At the early stage of the outbreak, most SARS-CoV-2-infected patients worked at or lived around the local Huanan seafood wholesale market. Among them severe acute respiratory infection symptoms were observed, and some patients even rapidly developed acute respiratory distress syndrome (ARDS), acute respiratory failure, and other serious complications [8].

Huang et al. first reported the clinical features of patients infected with SARS-CoV-2 in Wuhan, China [9]. A total of 41 patients admitted to hospital were identified as having laboratory-confirmed SARS-CoV-2 infection. Most of them were men ( $n=30$ , 73%). A minority of them had underlying diseases ( $n=13$ , 32%), including diabetes ( $n=8$ , 20%), hypertension ( $n=6$ , 15%), and cardiovascular disease ( $n=6$ , 15%). A majority of them ( $n=27$ , 66%) had been exposed to the Huanan seafood market, while one family cluster was found. Common symptoms at the onset of illness were fever ( $n=40$ , 98%), cough ( $n=31$ , 76%), and myalgia or fatigue ( $n=18$ , 44%); less common symptoms were sputum production (11/39, 28%), headache (3/38, 8%), hemoptysis (2/39, 5%), and diarrhea (1/38, 3%). All 41 patients had pneumonia with abnormal findings on chest computed tomography (CT). Complications included ARDS ( $n=12$ , 29%), RNAemia ( $n=6$ , 15%), acute cardiac in-

jury ( $n=5$ , 12%), and secondary infection ( $n=4$ , 10%). Among the 41 patients, 13 (32%) were admitted to the intensive care unit (ICU) and six (15%) died. Meanwhile, Zhu et al. described the clinical features of two SARS-CoV-2 pneumonia patients, evidenced by whole-genome sequencing, direct polymerase chain reaction (PCR), and virus isolation [10].

One week later, a larger retrospective study with 99 SARS-CoV-2-infected patients was reported [8]. In line with the previous findings, the SARS-CoV-2 infection showed a clustering onset, a higher likelihood of affecting older males with comorbidities, and the possibility of resulting in severe and even fatal respiratory diseases such as ARDS. In particular, some patients worsened in a short period of time and died of multiple organ failure. Subsequently, cases of SARS-CoV-2 infection were confirmed in the United States and Germany [11, 12].

Recently, another retrospective, single-center case series of 138 consecutive hospitalized patients with confirmed SARS-CoV-2 infection reported that hospital-related transmission of SARS-CoV-2 was suspected in 41% of the patients, 26% of the patients received ICU care, and the mortality rate was 4.3% [13].

Together, the clinical presentations of SARS-CoV-2 greatly resemble SARS-CoV. Patients with severe illness developed ARDS and required ICU admission and oxygen therapy.

## Cardiac involvement during SARS-CoV-2 infection

Previously published research mainly reported the epidemiological and clinical characteristics of SARS-CoV-2. Although elevated cardiac troponin I (cTnI) levels and arrhythmia were recorded, no specific investigation of the effects of SARS-CoV-2 infection on the cardiovascular system was reported.

In our clinical center, we mainly focused on the treatment of critically ill patients with severe SARS-CoV-2 infection, especially with cardiovascular complications. Among the 120 SARS-CoV-2-infected patients included in our observation, elevated N-terminal pro B-type natriuretic peptide (NT-proBNP;  $n=33$ , 27.5%) and cTnI ( $n=12$ , 10%) levels were recorded, indicating that the effects of cardiovascular injury on systemic stability should not be ignored.

The pathophysiology of SARS-CoV-2 has not been completely understood. Studies have suggested that SARS-CoV-2-infected patients had high levels of interleukin (IL)-1 beta, interferon gamma (IFN- $\gamma$ ), IFN inducible protein (IP)-10, and monocyte chemoattractant protein (MCP)-1, which probably led to the activated T-helper-1 cell response [9]. Moreover, they found that compared with patients who did not require ICU admission, those requiring ICU admission had higher concentrations of granulocyte colony-stimulating factor (GCSF), IP-10, MCP-1, macrophage inflammatory protein (MIP)-1A, and tumor necrosis factor (TNF)- $\alpha$ , suggesting that the cytokine storm might affect the disease severity [2]. We noticed that the plasma IL-6 level was increased dramatically in SARS-CoV-2-infected patients with cardiac injury. Moreover, death was associated with the cardiac damage induced by fulminant myocarditis (FM). Considering that a cytokine storm is also the core pathophysiological mechanism in FM—which is often fatal, especially in patients with severe multiple organ dysfunction—SARS-CoV-2-associated FM should be given more attention.

## Viral fulminant myocarditis

Fulminant myocarditis is a rare clinical syndrome with features of cardiac inflammation and a reported high mortality rate of approximately 40–70%. It is part of the clinical spectrum of acute myocarditis [14], but was not specifically mentioned in the Dallas Criteria [15] or in the report of the World Health Organization/International Society and Federation of Cardiology (WHO/ISFC) classification of cardiomyopathies [16].

According to the European Society of Cardiology (ESC) myocarditis taskforce classification [17] and the current literature on FM [18], FM can be categorized into the histologically defined entities of lymphocytic, eosinophilic, and giant cell myocarditis and sarcoid heart disease. The lymphocytic forms are subdivided into those of infective and noninfective origin. Whereas viral etiology is assumed but not proven in the majority of cases, biopsy studies of patients with acute myocarditis in Europe indicate that viral etiology ranges between 37.8% [19] and 77.4% [20]. In patients with severe heart failure (ejection fraction [EF] < 45%) and inflammation in the Marburg registry, 42.1% were virus positive.

The mortality rate of FM ranges from 40 to 70% in most centers [17, 21]. The current Chinese publication on “Life support-based comprehensive treatment regimen” demonstrated a mortality rate of less than 5% [22]. This treatment regimen included the early application of sufficient doses of immune-modulation drugs, e.g., sufficient doses of steroids and i.v. immunoglobins, neuraminidase inhibitors, and active mechanical life-support treatments. The life-support treatments comprised the application of mechanical respirators and circulatory support systems, of which intra-aortic balloon pulsation (IABP) or Impella implantation or extracorporeal membrane oxygenation (ECMO) as well as cardiac pacemaker are part of the current therapeutic armamentarium [23]. The important and life-saving role of IABP, Impella, and ECMO has been underlined also by European and American centers [24–26]. These measures follow

the hemodynamic principle of unloading the inflamed myocardium [27].

## Conclusion

**The condition of some patients with severe SARS-CoV-2 infection might deteriorate rapidly with acute respiratory distress syndrome and septic shock, which is eventually followed by multiple organ failure and fulminant myocarditis. More attention should be paid to patients with extremely increased cardiac troponin I (cTnI) levels and new-onset arrhythmias. The application of mechanical respirators and circulatory support systems, including IABP, Impella, and ECMO, might have beneficial effects on these patients.**

## Corresponding address

**Prof. Dao Wen Wang, MD, PhD**

Division of Cardiology, Department of Internal Medicine, and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology  
1095# Jiefang Ave., 430030 Wuhan, China  
dwwang@tjh.tjmu.edu.cn

**Acknowledgements.** We thank our colleagues from the Division of Cardiology, Tongji Hospital for their tremendous efforts during this investigation.

**Funding.** This work was supported by grants from the National Natural Science Foundation of China (91839302, 81630010, and 81790624) and Tongji Hospital Clinical Research Flagship Program (2019CR207). No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Conflict of interest.** C. Chen, Y. Zhou and D.W. Wang declare that they have no competing interests.

## References

1. Su S, Wong G, Shi W et al (2016) Epidemiology, genetic recombination, and pathogenesis of coronaviruses. *Trends Microbiol* 24(6):490–502. <https://doi.org/10.1016/j.tim.2016.03.003>
2. Ksiazek TG, Erdman D, Goldsmith CS et al (2003) A novel coronavirus associated with severe acute respiratory syndrome. *N Engl J Med* 348(20):1953–1966. <https://doi.org/10.1056/NEJMoa030781>
3. Zaki AM, van Boheemen S, Bestebroer TM et al (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *N Engl J Med* 367(19):1814–1820. <https://doi.org/10.1056/NEJMoa1211721>

4. Wang C, Horby PW, Hayden FG, Gao GF (2020) A novel coronavirus outbreak of global health concern. *Lancet*. [https://doi.org/10.1016/S0140-6736\(20\)30185-9](https://doi.org/10.1016/S0140-6736(20)30185-9)
5. Lu R, Zhao X, Li J et al (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet*. [https://doi.org/10.1016/S0140-6736\(20\)30251-8](https://doi.org/10.1016/S0140-6736(20)30251-8)
6. Zhou P, Yang XL, Wang XG et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. <https://doi.org/10.1038/s41586-020-1212-7>
7. Wu JT, Leung K, Leung GM (2020) Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *Lancet*. [https://doi.org/10.1016/S0140-6736\(20\)30260-9](https://doi.org/10.1016/S0140-6736(20)30260-9)
8. Chen N, Zhou M, Dong X et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. [https://doi.org/10.1016/S0140-6736\(20\)30211-7](https://doi.org/10.1016/S0140-6736(20)30211-7)
9. Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5)
10. Zhu N, Zhang D, Wang W et al (2020) A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med*. <https://doi.org/10.1056/NEJMoa2001017>
11. Shestakova EA, Motuz LP, Minin AA et al (1991) Some of eukaryotic elongation factor 2 is colocalized with actin microfilament bundles in mouse embryo fibroblasts. *Cell Biol Int Rep* 15(1):75–84. [https://doi.org/10.1016/0309-1651\(91\)90084-v](https://doi.org/10.1016/0309-1651(91)90084-v)
12. Rothe C, Schunk M, Sothmann P et al (2020) Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. *N Engl J Med*. <https://doi.org/10.1056/NEJMc2001468>
13. Wang D, Hu B, Hu C et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *J Am Med Assoc*. <https://doi.org/10.1001/jama.2020.1585>
14. Cooper LT Jr. (2009) Myocarditis. *N Engl J Med* 360(15):1526–1538. <https://doi.org/10.1056/NEJMra0800028>
15. Aretz HT, Billingham ME, Edwards WD et al (1987) Myocarditis. A histopathologic definition and classification. *Am J Cardiovasc Pathol* 1(1):3–14
16. Richardson P, McKenna W, Bristow M et al (1996) Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. *Circulation* 93(5):841–842. <https://doi.org/10.1161/01.cir.93.5.841>
17. Caforio AL, Pankuweit S, Arbustini E et al (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur Heart J* 34(33):2636–2648. <https://doi.org/10.1093/eurheartj/ehz210> (2648a–2648d)
18. Maisch B (2019) Cardio-immunology of myocarditis: focus on immune mechanisms and treatment options. *Front Cardiovasc Med* 6:48. <https://doi.org/10.3389/fcvm.2019.00048>
19. Pankuweit S, Moll R, Baandrup U et al (2003) Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens. *Hum Pathol* 34(5):497–503. [https://doi.org/10.1016/S0046-8177\(03\)00078-9](https://doi.org/10.1016/S0046-8177(03)00078-9)
20. Kuhl U, Pauschinger M, Noutsias M et al (2005) High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. *Circulation* 111(7):887–893. <https://doi.org/10.1161/01.CIR.0000155616.07901.35>
21. Ammirati E, Veronese G, Brambatti M et al (2019) Fulminant versus acute nonfulminant myocarditis in patients with left ventricular systolic dysfunction. *J Am Coll Cardiol* 74(3):299–311. <https://doi.org/10.1016/j.jacc.2019.04.063>
22. Li S, Xu S, Li C et al (2019) A life support-based comprehensive treatment regimen dramatically lowers the in-hospital mortality of patients with fulminant myocarditis: a multiple center study. *Sci China Life Sci* 62(3):369–380. <https://doi.org/10.1007/s11427-018-9501-9>
23. Wang D, Li S, Jiang J et al (2019) Chinese society of cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis. *Sci China Life Sci* 62(2):187–202. <https://doi.org/10.1007/s11427-018-9385-3>
24. Tschöpe C, Cooper LT, Torre-Amione G, Van Linthout S (2019) Management of myocarditis-related cardiomyopathy in adults. *Circ Res* 124(11):1568–1583. <https://doi.org/10.1161/CIRCRESAHA.118.313578>
25. Kociol RD, Cooper LT, Fang JC et al (2020) Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association. *Circulation*. <https://doi.org/10.1161/CIR.0000000000000745>
26. Spillmann F, Van Linthout S, Schmidt G et al (2019) Mode-of-action of the PROPELLA concept in fulminant myocarditis. *Eur Heart J* 40(26):2164–2169. <https://doi.org/10.1093/eurheartj/ehz124>
27. Tschöpe C, Van Linthout S, Klein O et al (2019) Mechanical unloading by fulminant myocarditis: LV-IMPELLA, ECMELLA, BI-PELLA, and PROPELLA concepts. *J Cardiovasc Transl Res* 12(2):116–123. <https://doi.org/10.1007/s12265-018-9820-2>

## Entwicklung kardiovaskuläre Medizin 2019

Schwerpunktheft zu wichtigen Publikationen und Daten des vergangenen Jahres



In dieser Ausgabe bieten wir Ihnen kommentierende Reviews zu neuen wichtigen Publikationen und Daten des vergangenen Jahres 2019 an.

Ob sich aus den letztjährigen Entwicklungen neue Aspekte zu verändertem diagnostischem und/oder therapeutischem Vorgehen ergeben, erfahren Sie in *Der Kardiologe* 02/2020 in folgenden Beiträgen.

- Jahresrückblick ischämische Herzerkrankung
- Herzklappenerkrankungen 2019
- Neuigkeiten Elektrophysiologie
- Elektrische Implantate
- Update Therapie der Herzinsuffizienz 2019
- Kardiologische Rehabilitation
- Wissenschaftslandschaft Deutschland

### Suchen Sie noch mehr zum Thema?

Mit e.Med – den maßgeschneiderten Fortbildungsabos von Springer Medizin – haben Sie Zugriff auf alle Inhalte von SpringerMedizin.de. Sie können schnell und komfortabel in den für Sie relevanten Zeitschriften recherchieren und auf alle Inhalte im Volltext zugreifen.

Weitere Infos zu e.Med finden Sie auf [springermedizin.de](https://www.springermedizin.de) unter „Abos“